Delinia is a biotechnology company developing novel therapeutics for the treatment of autoimmune diseases. Delinia’s lead program is a molecule that potentiates and expands Regulatory T Cells (Tregs), powerful immune cells that are critical to maintaining self-tolerance and immune system homeostasis. Tregs are critically important immune regulatory cells in the pathophysiology of cancer and autoimmune disease.
Delinia was acquired by Celgene Corporation.
Delinia was acquired by Celgene Corporation.
Total raised: $35M
Investors 1
| Date | Name | Website |
| - | Sofinnova ... | sofinnovap... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 14.09.2016 | Series A | $35M | - |
Mentions in press and media 5
| Date | Title | Description |
| 30.01.2017 | Term Sheet — Monday, January 30 | THE WEEKEND The tech industry has found its backbone, making increasingly bold statements and donations in reaction to President Trump’s order to deny entry to refugees and citizens of predominantly Muslim countries over the weekend. It cul... |
| 26.01.2017 | Celgene acquires autoimmune startup Delinia for $775M | As recently as September 2016, Delinia was a fledgling autoimmune startup, launching with just four full-time staff and a $35 million Series A co-led by Sofinnova Partners and Atlas Venture. Five months later it’s a very different story. Au... |
| 14.09.2016 | Delinia Raises $35M in Series A Financing | Delinia, a Cambridge, Massachusetts-based new company developing novel therapeutics that rebalance the immune system to treat serious and life-threatening autoimmune diseases, closed a $35m Series A funding. The round was co-led by Sofinnov... |
| 14.09.2016 | Delinia Announces $35M Series A | CAMBRIDGE, MA, New company developing novel therapeutics that rebalance the immune system to treat serious and life-threatening autoimmune diseases, has closed a $35M Series A investment. >> Click here for more funding data on Deli... |
| - | Celgene acquires autoimmune startup Delinia for $775M | On Thursday, Summit, New Jersey-based Celgene Corporation announced plans to acquire Delinia for an upfront $300 million and an additional $475 million in milestone-based payments. The transaction is expected to close in the first quarter o... |